FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg
Executive Summary
FDA's proposed rule to update the format of the pregnancy and lactation sections of drug labeling does not require the firms collect new data about their products, but the agency is hoping to use various mechanisms to encourage them to do so
You may also be interested in...
FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules
FDA’s prescription drug regulations in the works include rules on generic drug labeling, compounding, bioequivalence reports and safety reporting for combination products.
Drug Safety In Pregnant Women: FDA Seeks Alternatives To Registries
Stakeholder meeting will address poor enrollment rates and other issues that undermine the utility of pregnancy registries, as well as the use of alternatives, such as case control studies and claims-based database studies.
FDA Labeling Change Rule Is Most Prominent Item On Agency’s To-Do List
HHS’s semi-annual inventory of rulemaking actions under development includes six prescription drug-related rules.